The scale-up, promotion and use of oral pre-exposure prophylaxis (PrEP) in different settings and in different populations.

PrEP programmes and uptake: latest news

PrEP programmes and uptake resources

  • How to get PrEP in the UK

    In England, PrEP is available to people taking part in the PrEP Impact trial.In Wales, Scotland and Northern Ireland, PrEP is available through NHS sexual health clinics.It...

    From: Factsheets

    Information level Level 2

PrEP programmes and uptake news from aidsmap

  • People stay on PrEP for 14 months on average in the US, study finds

    Whether HIV pre-exposure prophylaxis (PrEP) is effective depends on whether people take it appropriately, at the times when they are at risk of HIV. But we know surprisingly little about how people receiving PrEP through health services take PrEP, ...

    10 March 2019 | Gus Cairns
  • How many people who have used PrEP get HIV the same year? New York study finds out

    One question often asked about pre-exposure prophylaxis (PrEP) use is how frequently people start PrEP while unknowingly having HIV, often because they have acquired it so recently that they are still in the ‘window period’ when it cannot ...

    07 March 2019 | Gus Cairns
  • Cocaine use associated with poor adherence to PrEP and dropping out of care

    Cocaine users have poorer adherence to HIV pre-exposure prophylaxis (PrEP) and engagement with care, according to research published in the online edition of the Journal of Acquired Immune Deficiency Syndromes. Even light cocaine use doubled the odds of having ...

    22 February 2019 | Michael Carter
  • In the USA, only two in five PrEP users keep taking it over two years

    Real-world data from a large American chain of retail pharmacies show that only two in five people keep on taking pre-exposure prophylaxis (PrEP) for two years after starting, researchers report in the Journal of the International AIDS Society this ...

    21 February 2019 | Roger Pebody
  • Gay men in New York rate an undetectable viral load as less effective than PrEP

    Gay, bisexual and other men who have sex with men in New York City rate daily pre-exposure prophylaxis (PrEP) as the most effective HIV prevention strategy when condoms aren’t used, and considerably more effective than treatment as prevention or ...

    19 February 2019 | Roger Pebody
  • PrEP promotion should be positive and inclusive

    Pre-exposure prophylaxis (PrEP) programmes should adopt modern marketing strategies that are attractive to healthy individuals and that might promote an inclusive and holistic vision of PrEP, Dr K Rivet Amico and Professor Linda-Gail Bekker argue in an opinion ...

    25 January 2019 | Roger Pebody
  • How did Kenya build Africa’s largest PrEP programme?

    Around 25,000 people are taking pre-exposure prophylaxis (PrEP) in Kenya, making it Africa’s largest PrEP programme, ahead of South Africa (9000 people), Uganda (4000) and Zimbabwe (4000). The roll-out was recently described by officials from Kenya’s Ministry of Health ...

    25 January 2019 | Roger Pebody
  • Growth in positive attitudes towards PrEP among Australian gay and bisexual men

    Willingness to consider using pre-exposure prophylaxis (PrEP) increased between 2011 and 2017 among gay and bisexual men in Australia, while concerns about using it decreased, according to research published in AIDS and Behavior. Community support for PrEP users remained solid.“We ...

    08 January 2019 | Michael Carter
  • Six innovative models for PrEP services

    For pre-exposure prophylaxis (PrEP) to have a substantial public health impact, access to PrEP needs to be improved so that more people who would benefit from it receive PrEP. Services need to adapt and innovate. A series of ...

    07 January 2019 | Roger Pebody
  • HIV infections among black gay men taking PrEP, probably due to poor adherence

    Awareness and use of HIV pre-exposure prophylaxis (PrEP) among black gay, bisexual and other men who have sex with men (MSM) in the United States increased significantly between 2014 and 2017, according to research published in the 1 November ...

    20 December 2018 | Michael Carter
More news

PrEP programmes and uptake news selected from other sources

More news
Tell us why you visited aidsmap today
minimise

Could you help us by answering three questions on why you’ve visited aidsmap today?

You can close this questionnaire and come back to it later. Just click on the pink circle.

What prompted you to visit aidsmap today?

What exactly are you looking for? What specific questions do you need answered?

Have you found what you were looking for?

close

Thank you for your feedback

Thank you very much for taking time to fill in this questionnaire. NAM really values your feedback. It helps make the information we provide better.

If you have any other comments on the content of this website, we would be interested to hear from you. Please email info@nam.org.uk.

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.